

GILUPI attends the ISMRC congress in Montpellier, France

GILUPI GmbH is pleased to announce its participation at the 2018 ISMRC (International Symposium on Minimal Residual Cancer) congress.

The 11th ISMRC symposium will take place from 3rd to 5th of May in Montpellier, France and is focused on "Minimal Residual Cancer in patients with solid tumors". This congress brings together researchers from academia and industry sharing information about liquid biopsy. The program will include presentations on Circulating Tumor Cells (CTCs) as well as circulating nucleic acids (DNA, miRNA) and exosomes with an emphasis on clinical studies and the biology of metastasis.

GILUPI will use this opportunity to present data from clinical settings with focus on therapy-relevant targets in lung and prostate cancer detected on CTCs by using the *in vivo* GILUPI CellCollector® technology. The poster presentation (P-54) will take place on Thursday 3rd of May at 2.30 pm - 3.20 pm. You are invited to meet the CEO of GILUPI Dr. Christian Jurinke.

About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is todays challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immunocapture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA-and RNA-based methods, isolated cells can be characterized and/or analyzed down to a molecular level.

The GILUPI CellCollector® is the first *in vivo* CTC isolation product worldwide that is CE approved.

For further information visit www.gilupi.com